The Pink Bow nonprofit

Proposed Legislation: Comprehensive Ban on Phytoestrogenic Substances, Flax, Soy, and Mandatory Warning Labels 

Introduction: The Urgent Need to Address Phytoestrogens 

Phytoestrogens,  plant-based forms of estrogen, directly elevate estrogen levels in the  body, leading to severe hormonal imbalances with profound health and  societal consequences. Unlike synthetic estrogens or xenoestrogens such as Atrazine, phthalates, BPA, etc., phytoestrogens are consumed in large quantities daily, amplifying their disruptive impact. A single gram of phytoestrogens is 1 billion times stronger than a nanogram of these synthetic compounds, making their pervasive presence in food and  products a significant threat to public health. 

These hormonal disruptors have been scientifically linked to: 

• Disrupt fertility, contributing to decreased sperm counts and reduced conception rates. 
• Cause early puberty and hormonal imbalances that lead to gender identity confusion. 
• Result in the feminization of boys and masculinization of girls, creating developmental and societal concerns. 
• Increase the risk of hormone-sensitive cancers, including breast cancer and uterine cancer. 
• These conditions are preventable, as they are attributable to exogenous estrogens: PMS, PCOS, menopause symptoms, fibroids/masses, infertility, breast and uterine cancer, early puberty, gender dysphoria, feminization of boys, masculinization of girls, low testosterone, and sterility. 

The  introduction of soy and flax into the modern diet has created a silent  public health crisis, as these substances are marketed as "health foods"  despite their estrogenic effects. This bill proposes a comprehensive  ban on phytoestrogenic substances, mandatory warning labels for  whole-food sources, and public education campaigns to mitigate their widespread and damaging effects on individual health, fertility, and  societal stability. Immediate action is necessary to safeguard future generations and restore hormonal balance in the population.  

Section 1: Regulation of Phytoestrogenic Substances Flax and Soy 

A. Prohibition on Phytoestrogenic Substances Flax and Soy
This bill seeks to prohibit the use, sale, and inclusion of phytoestrogenic substances  and their derivatives in all food products, dietary supplements, and  animal feed. Specifically, the following items are banned: 

• Flaxseed 
• Flax oil 
• Soy 
• Soy lecithin 
• Soy emulsifiers 
• Soya 
• Soy protein 
• Soy oil 
• Soy formula 
• All their derivatives 

B. Mandatory Warning Labels for Whole Food Phytoestrogen Sources
Products containing whole food forms of phytoestrogens, such as tofu, tempeh, edamame, and flaxseed, must display clear warning labels. 

Required Label Text:
WARNING:  This product is a phytoestrogen, which has been linked to an increased  risk of PMS, PCOS, menopause symptoms, fibroids/masses, infertility, pregnancy loss, breast and uterine cancer, early puberty, gender dysphoria,  feminization of boys, masculinization of girls, low testosterone, and  sterility. 

C. Rationale and Supporting Evidence  

1. Public Health Concerns: 

• Phytoestrogens are a plant-based form of estrogen that directly increases estrogen levels in the body,  contributing to hormonal imbalances that impact fertility, early  puberty, gender identity confusion, the feminization/masculinization of  children, excess estrogen levels in men and women along with breast and uterine cancer. 
• Scientific studies have demonstrated: 
• Turtle eggs exposed to phytoestrogens develop exclusively female offspring. 
• Japanese researchers altered catfish biology, increasing weight by turning all fish female with soy feed. 
• Transplacental transfer of soy compounds from mother to child has been documented, exposing fetuses to phytoestrogens in utero. 

Section 2. Hormonal Impact on Society:  Introduction of Soy in the Late 1970s: 

The  widespread inclusion of soy in the American food supply began in the  late 1970s, introducing significant levels of phytoestrogens into everyday diets. This shift has directly contributed to widespread  hormonal imbalances with profound societal effects. 

Breast Cancer Statistics: 

• Breast cancer rates have increased significantly since soy's introduction. By 1992, the rate rose from 1 in 11 women (1980) to 1 in 8, with 80% of breast cancer cases fueled by estrogen as identified in pathology reports or biopsy. 
• In men, breast cancer rates have risen by 1% annually since 1979, with researchers often citing "unknown reasons." 
• The promotion of soy as a health food has significantly influenced dietary trends in other countries.  For example, in Japan, breast cancer has now become the leading type of  cancer among women, highlighting the global impact of estrogenic  substances in diets. 

Testosterone Decline: 

• Male testosterone levels have been decreasing at an average rate of 1% annually since 1980, amounting to a 25% decline over the past 40 years. 
• Sperm counts have fallen by 52%, and at the current trajectory, sperm counts may reach zero by 2045, leading to widespread infertility. 

Increased Estrogen Exposure: 

• A single cup of soy milk delivers an estrogenic dose equivalent to one birth control pill, while ¼ cup of flaxseed equals 20 pills. 
• Soy  products, heavily marketed as health foods, are now a staple in many  diets, contributing to high daily phytoestrogen exposure. For example, an Impossible Burger contains 44 mg of estrogen—18 million times more than a Whopper, which contains only 2.5 ng.  

Section 3. Economic and Societal Costs:

a. Early Puberty and Hormonal Interventions: Early puberty affects 44% of girls aged  

7-8, with 14.3% of Black girls developing breasts or pubic hair by the age of 6. Of these, 15% require intervention, including the use of puberty blockers. Over the last five years, 4,780 adolescents have started puberty  blockers, reflecting a skyrocketing increase in such interventions. 

b. Rising Gender Dysphoria and LGBT Identification: Gender dysphoria rates have risen dramatically, with a 4,000% increase in  transgender identification among girls in England over the last decade.  Similarly, in the U.S., the number of transgender children seeking  treatments or surgeries nearly tripled, from 42,000 in 2017 to 121,000 by 2021. These trends align with broader societal shifts, including:  

• The percentage of individuals identifying as LGBT rising from 1.2% in 1990 to 5.5% in 2011-2013, and further to 7.1% by 2022. 
• Reports of same-sex experiences among women aged 16-44 increasing from 4% in 1990 to 16% by 2010. 

The  widespread introduction and consumption of phytoestrogens, substances known to disrupt hormone balance, may play a significant role in these  patterns, influencing both gender identity and sexual behaviors. 

Section 4. The Influence of Estrogen on Obesity 

The inclusion of soy and flax in animal feed is primarily intended to promote weight gain. Estrogen compounds found in these substances have been linked to increased fat accumulation. PhGiven the growing concerns about obesity rates in America, supporting the ban on soy and flax in animal feed is an important step toward addressing this issue. 

Section 5. The Infertility Epidemic   

This legislation acknowledges that the removal of xenoestrogens, such as Atrazine, Phthalates, pesticides, etc., alone will not reverse the ongoing decline in fertility. It is crucial to address phytoestrogens as the primary contributing factor in order to effectively improve fertility rates. mental health conditions. Our licensed therapists and counselors are here to provide compassionate, confidential support and guidance.

1. Approximately $4.5 trillion is spent annually on healthcare costs in the United States, with 80% of  these expenditures linked to chronic illnesses, including  hormone-related disorders. Despite this significant investment, the  United States has the lowest life expectancy among all developed  countries, highlighting the urgent need for effective interventions to  address the growing prevalence of chronic conditions. 
2. The global market for sex reassignment surgery is projected to exceed $1.5 billion by 2026, with an annual growth rate of 24.5%. This rapid expansion reflects the increasing demand for such procedures and the financial incentives tied to the proliferation of  hormone-disrupting substances like phytoestrogens. These economic forces  compound the societal and public health challenges, creating 
3. In 2023, the U.S. breast cancer drug market generated $28.1 billion in sales, with CDK4/6 inhibitors and HER2-targeting agents leading the  market. The market is projected to experience significant growth,  reaching an estimated $78.61 billion by 2033. 
4. Chronic health problems aren’t just creating a flow of income for corporations; they are financially crippling individuals. Medical debt is the number one cause of bankruptcy in the United States, locking families into a lifetime of debt and despair. RFK Jr. said, “There is nothing more profitable in our society today than a  sick child because all these entities are making money on the insurance  companies, the hospital, the medical cartel, the pharmaceutical  companies have a lifetime annuities…they want them sick for the rest of  their lives.”